XL413 HCl is an ATP-competitive Cdc7 inhibitor (IC50: 3.4 nM) that is potent and selective.XL413 HCl inhibited CK2 and PIM1 with IC50 values of 215 and 42 nM, respectively.XL413 HCl showed an EC50 value of 118 against pMCM.

CK2:215 nM, CDC7:3.4 nM, pMCM:118 nM(EC50), Pim1:42 nM

XL413 HCl shows cytotoxic effects on tumors, with IC50 of 22.9 µM in HCC1954 cells and 1.1 µM in Colo-205 cells.[2]
BMS-863233 HCl is an effective DDK inhibitor in vitro, with an IC50 of 22.7 nM.[2]
XL413 HCl is defective in inhibiting DDK-dependent Mcm2 phosphorylation in HCC1954 cells but is effective in Colo-205 cells.[2]

XL413 HCl (10, 30, or 100 mg/kg; p.o.; mice) is well tolerated at all doses, with no significant body weight loss.[1]
XL413 HCl (100 mg/kg; p.o.; mice) show excellent plasma exposures in mice and possesses good PK properties.[1]

H2O: 9.00 mg/mL (27.59 mM), Sonication is recommended.

DMSO: 3.10 mg/mL (9.50 mM), Sonication and heating are recommended.